BL-M07D1 versus chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer

A Phase III Randomized Controlled Clinical Study of BL-M07D1 for Injection Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (G/GEJ) Adenocarcinoma After Failure of First-line Anti-HER2 Therapy

This trial tests whether BL-M07D1 works better than a doctor's choice of chemotherapy for adults with HER2‑positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after first‑line anti‑HER2 therapy has failed.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 490 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy, prednisone
• Locations: 2 sites (Harbin, Heilongjiang and 1 other locations)
• Trial ID: NCT07152405 on ClinicalTrials.gov

What this trial studies

This is a randomized, open‑label Phase III multicenter trial comparing BL‑M07D1 with investigator‑chosen chemotherapy in adults with HER2‑positive unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after progression on first‑line anti‑HER2 therapy and standard chemotherapy. Participants must have at least one measurable lesion per RECIST v1.1, ECOG performance status 0–1, and adequate organ and cardiac function. The study will collect efficacy outcomes such as progression‑free survival and overall survival as well as safety and tolerability data. Trial sites listed include major cancer centers in China.

Who should consider this trial

Good fit: Adults 18–75 with histologically or cytologically confirmed unresectable locally advanced or metastatic HER2‑positive gastric or GEJ adenocarcinoma who progressed after first‑line anti‑HER2 therapy and standard chemotherapy, have a measurable lesion, ECOG 0–1, and adequate organ and cardiac function are the intended candidates.

Not a fit: Patients with ECOG performance status ≥2, severe cardiac dysfunction or low LVEF, uncontrolled comorbidities, inadequate organ function, life expectancy under three months, or tumors that are not HER2‑positive are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, BL‑M07D1 could provide a more effective treatment option and potentially extend progression‑free and overall survival for patients whose disease progressed after first‑line anti‑HER2 therapy.

How similar studies have performed: HER2‑targeted approaches have demonstrated clinical benefit in gastric cancer—trastuzumab is established in first‑line therapy and antibody‑drug conjugates like trastuzumab deruxtecan have shown efficacy in later lines—so this strategy has precedent and recent successes.

Eligibility criteria

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. No gender restrictions;
3. Age at the time of signing the informed consent form is ≥18 years and ≤75 years;
4. Expected survival time ≥3 months;
5. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma;
6. Must have at least one measurable target lesion as defined by RECIST v1.1;
7. ECOG performance status score of 0 or 1;
8. Toxicity from previous antitumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
9. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
10. Organ function levels must meet the requirements;
11. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN;
12. Urine protein ≤2+ or \<1000mg/24h;
13. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must be negative. Patients must not be lactating. All enrolled patients (regardless of gender) should adopt adequate barrier contraception methods throughout the treatment cycle and for 7 months after the end of treatment.

Exclusion Criteria:

1. Received chemotherapy with mitomycin C and nitrosoureas within 6 weeks prior to the first dose, or underwent major surgery, radical radiotherapy, immunotherapy, etc., within 4 weeks prior to the first dose;
2. Previous treatment with HER2-ADC drugs, or ADC drugs with topoisomerase 1 inhibitors as the payload, or prior irinotecan therapy;
3. History of severe cardiovascular or cerebrovascular diseases within the past 6 months before screening;
4. Prolonged QT interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrollable arrhythmias;
5. Concurrent pulmonary diseases resulting in severe impairment of lung function;
6. History of interstitial lung disease (ILD)/interstitial pneumonia requiring steroid treatment, or current ILD/interstitial pneumonia;
7. Diagnosis of other primary malignancies within 3 years prior to the first dose;
8. Poorly controlled hypertension (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg);
9. Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (leptomeningeal metastases);
10. History of allergy to recombinant humanized antibodies or any excipient components of BL-M07D1;
11. History of autologous or allogeneic stem cell transplantation;
12. Unstable deep vein thrombosis requiring anticoagulant therapy during the screening period, or newly diagnosed deep vein thrombosis within 14 days;
13. Positive human immunodeficiency virus (HIV) antibody, active hepatitis B virus infection, or hepatitis C virus infection;
14. Occurrence of severe infections within 4 weeks prior to the first dose of the investigational drug; presence of infections requiring systemic treatment during the screening period;
15. Patients with massive serous cavity effusion, symptomatic serous cavity effusion, or poorly controlled serous cavity effusion;
16. Long-term systemic corticosteroid therapy (\>10 mg/d prednisone or equivalent anti-inflammatory activity) or any form of immunosuppressive therapy within 2 weeks prior to randomization;
17. History of severe neurological or psychiatric disorders;
18. Presence of severe unhealed wounds, ulcers, or fractures within 4 weeks prior to signing the informed consent;
19. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing the informed consent;
20. Conditions such as intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea;
21. Subjects planning to receive or having received live vaccines within 28 days prior to the first dose;
22. Presence of other severe physical or laboratory abnormalities, poor compliance, or any other factors that may increase the risk of participation in the study, interfere with study results, or make the patient unsuitable for participation in the study as determined by the investigator.

Where this trial is running

Harbin, Heilongjiang and 1 other locations

• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (Recruiting)
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Sa Xiao, PHD

Conditions Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma